Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
Nat Med. 2021 Jan;27(1):115-124. doi: 10.1038/s41591-020-1105-z. Epub 2020 Nov 9.
We developed a metagenomic next-generation sequencing (mNGS) test using cell-free DNA from body fluids to identify pathogens. The performance of mNGS testing of 182 body fluids from 160 patients with acute illness was evaluated using two sequencing platforms in comparison to microbiological testing using culture, 16S bacterial PCR and/or 28S-internal transcribed ribosomal gene spacer (28S-ITS) fungal PCR. Test sensitivity and specificity of detection were 79 and 91% for bacteria and 91 and 89% for fungi, respectively, by Illumina sequencing; and 75 and 81% for bacteria and 91 and 100% for fungi, respectively, by nanopore sequencing. In a case series of 12 patients with culture/PCR-negative body fluids but for whom an infectious diagnosis was ultimately established, seven (58%) were mNGS positive. Real-time computational analysis enabled pathogen identification by nanopore sequencing in a median 50-min sequencing and 6-h sample-to-answer time. Rapid mNGS testing is a promising tool for diagnosis of unknown infections from body fluids.
我们开发了一种基于体液无细胞 DNA 的宏基因组下一代测序 (mNGS) 检测方法,用于鉴定病原体。通过比较培养、16S 细菌 PCR 和/或 28S-内部转录间隔区(28S-ITS)真菌 PCR 等微生物检测方法,评估了该 mNGS 检测方法在 160 名急性疾病患者的 182 种体液中的性能。Illumina 测序的检测细菌的灵敏度和特异性分别为 79%和 91%,真菌分别为 91%和 89%;而纳米孔测序的灵敏度和特异性分别为 75%和 81%,真菌分别为 91%和 100%。在 12 例培养/PCR 阴性体液但最终确定为感染性疾病的病例系列中,7 例(58%)mNGS 阳性。实时计算分析使纳米孔测序能够在中位 50 分钟测序和 6 小时样本到答案时间内识别病原体。快速 mNGS 检测是一种很有前途的工具,可用于诊断体液中的未知感染。